A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
Phase 1
168
about 2.1 years
18+
6 sites in CA, CT, MN +3
What this study is about
Researchers are testing a new treatment called BG-C137 to see if it's safe and effective for people with advanced solid tumors. The trial will involve giving BG-C137 alone or in combination with other cancer treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Anticancer Agents
- 2.Take BG-C137
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-C137, Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Phase 1b: Overall Response Rate (ORR)
Secondary: Phase 1a and 1b: Disease Control Rate (DCR), Phase 1a and 1b: Duration of Response (DOR), Phase 1a: Area Under the Plasma Concentration-time Curve (AUC) of BGB-C137 analytes, Phase 1a: Maximum observed plasma concentration (Cmax) of BGB-C137 analytes, Phase 1a: ORR, Phase 1a: Terminal Half-Life (t1/2) of BGB-C137 analytes, Phase 1a: Time to reach maximum observed plasma concentration (Tmax) of BGB-C137 analytes, Phase 1b: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Oncology